Psychological Aspects of Cutaneous Pain in Psoriasis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Disease Severity Assessment
2.2. Pain Assessment
2.3. Psychosocial Burden
2.3.1. Hospital Anxiety and Depression Scale
2.3.2. Generalized Anxiety Disorder-7
2.3.3. Patient Health Questionnaire-9
2.3.4. Dermatology Life Quality Index
2.3.5. 6-Item Stigmatization Scale
2.4. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cohen, S.P.; Vase, L.; Hooten, W.M. Chronic pain: An update on burden, best practices, and new advances. Lancet 2021, 397, 2082–2097. [Google Scholar] [CrossRef]
- Johnston, K.J.; Huckins, L.M. Chronic Pain and Psychiatric Conditions. Complex Psychiatry 2022, 9, 24–43. [Google Scholar] [CrossRef]
- Velly, A.M.; Mohit, S. Epidemiology of pain and relation to psychiatric disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2018, 87, 159–167. [Google Scholar] [CrossRef] [PubMed]
- Krajewski, P.; von Stebut, E.; Schultheis, M.; Kirschner, U.; Nikolakis, G.; Szepietowski, J. Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1795 Patients. Acta Derm. Venereol. 2021, 101, adv00364. [Google Scholar] [CrossRef]
- Yosipovitch, G.; Aroman, M.S.; Taieb, C.; Sampogna, F.; Carballido, F.; Reich, A. Skin pain: A symptom to be investigated. J. Am. Acad. Dermatol. 2023, 88, 479–481. [Google Scholar] [CrossRef] [PubMed]
- Misery, L.; Aroman, M.; Zkik, A.; Briant, A.; Martin, L.; Sigal, M.; Bodemer, C.; Guillet, G.; Bagot, M.; Taïeb, C. Chronic Pain in Patients with Skin Disorders. Acta Derm. Venereol. 2017, 97, 986–988. [Google Scholar] [CrossRef]
- Michalek, I.; Loring, B.; John, S. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 205–212. [Google Scholar] [CrossRef]
- Rapp, S.R.; Feldman, S.R.; Exum, M.L.; Fleischer, A.B., Jr.; Reboussin, D.M. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 1999, 41, 401–407. [Google Scholar] [CrossRef] [PubMed]
- Haraldstad, K.; Wahl, A.; Andenæs, R.; Andersen, J.R.; Andersen, M.H.; Beisland, E.; Borge, C.R.; Engebretsen, E.; Eisemann, M.; Halvorsrud, L.; et al. A systematic review of quality of life research in medicine and health sciences. Qual. Life Res. 2019, 28, 2641–2650. [Google Scholar] [CrossRef]
- Szepietowski, J.; Hrehorów, E.; Salomon, J.; Reich, A. Patients with Psoriasis Feel Stigmatized. Acta Derm. Venereol. 2012, 92, 67–72. [Google Scholar] [CrossRef]
- Pettey, A.; Balkrishnan, R.; Rapp, S.R.; Fleischer, A.B.; Feldman, S.R. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice. J. Am. Acad. Dermatol. 2003, 49, 271–275. [Google Scholar] [CrossRef]
- Husted, J.A.; Gladman, D.D.; Farewell, V.T.; Cook, R.J. Health-related quality of life of patients with psori-atic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001, 45, 151–158. [Google Scholar] [CrossRef]
- Kimball, A.B.; Jacobson, C.; Weiss, S.; Vreeland, M.G.; Wu, Y. The Psychosocial Burden of Psoriasis. Am. J. Clin. Dermatol. 2005, 6, 383–392. [Google Scholar] [CrossRef]
- Sampogna, F.; Gisondi, P.; Melchi, C.; Amerio, P.; Girolomoni, G.; Abeni, D. The Idi Multipurpose Psoriasis Research on Vital Experiences (Improve) Investigators Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br. J. Dermatol. 2004, 151, 594–599. [Google Scholar] [CrossRef]
- Elewski, B.; Alexis, A.F.; Lebwohl, M.; Gold, L.S.; Pariser, D.; Del Rosso, J.; Yosipovitch, G. Itch: An under-recognized problem in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2019, 33, 1465–1476. [Google Scholar] [CrossRef] [PubMed]
- Mrowietz, U.; Kragballe, K.; Reich, K.; Spuls, P.; Griffiths, C.E.M.; Nast, A.; Franke, J.; Antoniou, C.; Arenberger, P.; Balieva, F.; et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 2011, 303, 1–10. [Google Scholar] [CrossRef]
- Cheung, H.N.; Chan, Y.S.; Hsiung, N.H. Validation of the 5-D Itch Scale in Three Ethnic Groups and Exploring Optimal Cutoff Values Using the Itch Numerical Rating Scale. BioMed Res. Int. 2021, 2021, 7640314. [Google Scholar] [CrossRef] [PubMed]
- Hawker, G.A.; Mian, S.; Kendzerska, T.; French, M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthr. Care Res. 2011, 63, S240–S252. [Google Scholar] [CrossRef]
- Melzack, R. The short-form McGill pain questionnaire. Pain 1987, 30, 191–197. [Google Scholar] [CrossRef]
- da Costa, B.; Saadat, P.; Basciani, R.; Agarwal, A.; Johnston, B.; Jüni, P. Visual Analogue Scale has higher assay sensitivity than WOMAC pain in detecting between-group differences in treatment effects: A meta-epidemiological study. Osteoarthr. Cartil. 2021, 29, 304–312. [Google Scholar] [CrossRef] [PubMed]
- Bocéréan, C.; Dupret, E. A validation study of the Hospital Anxiety and Depression Scale (HADS) in a large sample of French employees. BMC Psychiatry 2014, 14, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Szabó, Á.; Brodszky, V.; Rencz, F. A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI-Relevant and Skindex-16*. Br. J. Dermatol. 2022, 186, 485–495. [Google Scholar] [CrossRef]
- Spitzer, R.L.; Kroenke, K.; Williams, J.B.W.; Löwe, B. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7: The GAD-7. Arch. Intern. Med. 2006, 166, 1092–1097. [Google Scholar] [CrossRef]
- Kroenke, K.; Spitzer, R.L.; Williams, J.B. The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16, 606–613. [Google Scholar] [CrossRef] [PubMed]
- Dimitrov, D.; Szepietowski, J.C. Instruments to assess stigmatization in dermatology. Postepy Hig. I Med. Doswiadczalnej 2017, 71, 901–905. [Google Scholar] [CrossRef] [PubMed]
- Lu, Y.; Duller, P.; van der Valk, P.; Evers, A. Helplessness as Predictor of Perceived Stigmatization in Patients with Psoriasis and Atopic Dermatitis. Dermatol. Psychosom. Dermatol. Psychosom. 2003, 4, 146–150. [Google Scholar] [CrossRef]
- Ferreira, B.R.; Pio-Abreu, J.L.; Reis, J.P.; Figueiredo, A. Analysis of the Prevalence of Mental Disorders in Psoriasis: The Relevance of Psychiatric Assessment in Dermatology. Psychiatr. Danub. 2017, 29, 401–406. [Google Scholar] [CrossRef]
- Dowlatshahi, E.A.; Wakkee, M.; Arends, L.R.; Nijsten, T. The Prevalence and Odds of Depressive Symptoms and Clinical Depression in Psoriasis Patients: A Systematic Review and Meta-Analysis. J. Investig. Dermatol. 2014, 134, 1542–1551. [Google Scholar] [CrossRef]
- Adesanya, E.I.; Matthewman, J.; Schonmann, Y.; Hayes, J.F.; Henderson, A.; Mathur, R.; Mulick, A.R.; Smith, C.H.; Langan, S.M.; E Mansfield, K. Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: A systematic review and meta-analysis. Br. J. Dermatol. 2023, 188, 460–470. [Google Scholar] [CrossRef]
- Luna, P.C.; Chu, C.-Y.; Fatani, M.; Borlenghi, C.; Adora, A.; Llamado, L.Q.; Wee, J. Psychosocial Burden of Psoriasis: A Systematic Literature Review of Depression Among Patients with Psoriasis. Dermatol. Ther. 2023, 13, 3043–3055. [Google Scholar] [CrossRef]
- Jalenques, I.; Bourlot, F.; Martinez, E.; Pereira, B.; D’Incan, M.; Lauron, S.; Rondepierre, F. Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysi. Acta Derm. -Venereol. 2022, 102, adv00769. [Google Scholar] [CrossRef] [PubMed]
- Dalgard, F.J.; Gieler, U.; Tomas-Aragones, L.; Lien, L.; Poot, F.; Jemec, G.B.; Misery, L.; Szabo, C.; Linder, D.; Sampogna, F.; et al. The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries. J. Investig. Dermatol. 2015, 135, 984–991. [Google Scholar] [CrossRef] [PubMed]
- Koo, J.; Marangell, L.; Nakamura, M.; Armstrong, A.; Jeon, C.; Bhutani, T.; Wu, J. Depression and suicidality in psoriasis: Review of the literature including the cytokine theory of depression. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 1999–2009. [Google Scholar] [CrossRef] [PubMed]
- Dowlati, Y.; Herrmann, N.; Swardfager, W.; Liu, H.; Sham, L.; Reim, E.K.; Lanctôt, K.L. A Meta-Analysis of Cytokines in Major Depression. Biol. Psychiatry 2010, 67, 446–457. [Google Scholar] [CrossRef]
- Schiepers, O.J.; Wichers, M.C.; Maes, M. Cytokines and major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29, 201–217. [Google Scholar] [CrossRef] [PubMed]
- Tabra, S.A.; Elghany, S.E.A.; Amer, R.A.; Fouda, M.H.; Abu-Zaid, M.H. Serum interleukin-23 levels: Relation to depression, anxiety, and disease activity in psoriatic arthritis patients. Clin. Rheumatol. 2022, 41, 3391–3399. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.J.; Bin Wei, Y.; Strawbridge, R.; Bao, Y.; Chang, S.; Shi, L.; Que, J.; Gadad, B.S.; Trivedi, M.H.; Kelsoe, J.R.; et al. Peripheral cytokine levels and response to antidepressant treatment in depression: A systematic review and meta-analysis. Mol. Psychiatry 2020, 25, 339–350. [Google Scholar] [CrossRef] [PubMed]
- Fleming, P.; Roubille, C.; Richer, V.; Starnino, T.; McCourt, C.; McFarlane, A.; Siu, S.; Kraft, J.; Lynde, C.; Pope, J.; et al. Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 1063–1070. [Google Scholar] [CrossRef] [PubMed]
- Raber, J.; O’shea, R.D.; Bloom, F.E.; Campbell, I.L. Modulation of Hypothalamic–Pituitary–Adrenal Function by Transgenic Expression of Interleukin-6 in the CNS of Mice. J. Neurosci. 1997, 17, 9473–9480. [Google Scholar] [CrossRef] [PubMed]
- Patruno, C.; Napolitano, M.; Balato, N.; Ayala, F.; Megna, M.; Patrì, A.; Cirillo, T.; Balato, A. Psoriasis and Skin Pain: Instrumental and Biological Evaluations. Acta Derm. Venereol. 2015, 95, 432–438. [Google Scholar] [CrossRef] [PubMed]
- Misery, L.; Shourick, J.; Taieb, C. Skin pain and psoriasis. J. Am. Acad. Dermatol. 2020, 83, 245–246. [Google Scholar] [CrossRef]
- Ljosaa, T.; Mork, C.; Stubhaug, A.; Moum, T.; Wahl, A. Skin pain and skin discomfort is associated with quality of life in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2012, 26, 29–35. [Google Scholar] [CrossRef]
- García-Fernández, L.; Belinchón-Romero, I.; Pastor-Tomás, N.; Lucas-Costa, A.; Marín-Cabañas, I.; Ramos-Rincón, J.M. Pruritus and skin pain in psoriatic patients: The neglected symptoms. Eur. J. Dermatol. 2019, 29, 429–430. [Google Scholar] [CrossRef]
- Ljosaa, T.; Rustoen, T.; Mørk, C.; Stubhaug, A.; Miaskowski, C.; Paul, S.; Wahl, A. Skin Pain and Discomfort in Psoriasis: An Exploratory Study of Symptom Prevalence and Characteristics. Acta Derm. Venereol. 2010, 90, 39–45. [Google Scholar] [CrossRef]
- Hayoun-Vigouroux, M.; Misery, L. Dermatological Conditions Inducing Acute and Chronic Pain. Acta Dermato-Venereologica 2022, 102, adv00742. [Google Scholar] [CrossRef] [PubMed]
- Chiu, I.M.; A von Hehn, C.; Woolf, C.J. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat. Neurosci. 2012, 15, 1063–1067. [Google Scholar] [CrossRef]
- Gupta, K.; Harvima, I.T. Mast cell-neural interactions contribute to pain and itch. Immunol. Rev. 2018, 282, 168–187. [Google Scholar] [CrossRef]
- Vakharia, P.P.; Chopra, R.; Sacotte, R.; Patel, K.R.; Singam, V.; Patel, N.; Immaneni, S.; White, T.; Kantor, R.; Hsu, D.Y.; et al. Burden of skin pain in atopic dermatitis. Ann. Allergy Asthma Immunol. 2017, 119, 548–552.e3. [Google Scholar] [CrossRef]
- Zalewski, A.; Krajewski, P.K.; Szepietowski, J.C. Psychosocial Consequences of Hand Eczema—A Prospective Cross-Sectional Study. J. Clin. Med. 2023, 12, 5741. [Google Scholar] [CrossRef] [PubMed]
- Kendel, F.; Wirtz, M.; Dunkel, A.; Lehmkuhl, E.; Hetzer, R.; Regitz-Zagrosek, V. Screening for depression: Rasch analysis of the dimensional structure of the PHQ-9 and the HADS-D. J. Affect. Disord. 2010, 122, 241–246. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Whole Population (n = 106) | Females (n = 36) | Males (n = 70) | p |
---|---|---|---|---|
Age, years (mean ± SD) | 42.07 ± 12.96 | 39.94 ± 14.00 | 43.16 ± 12.35 | NS |
PASI [points] (mean ± SD) | 10.93 ± 8.47 | 10.18 ± 9.87 | 11.32 ± 7.71 | NS |
Disease duration, years (mean ± SD) | 14.89 ± 12.69 | 15.00 ± 12.23 | 14.83 ± 13.00 | NS |
Family history of psoriasis | 50 (47.2%) | 21 (58.3%) | 29 (41.4%) | NS |
Pain in the past week | 53 (50%) | 20 (55.6%) | 33 (47.1%) | NS |
Pain NRS in the past week [points] (mean ± SD) | 2.42 ± 2.96 | 3.06 ± 3.30 | 2.09 ± 2.73 | NS |
SF-MPQ Total score [points] (mean ± SD) | 4.84 ± 7.51 | 5.89 ± 8.05 | 4.30 ± 7.22 | NS |
SF-MPQ sensory [points] (mean ± SD) | 3.85 ± 6.03 | 4.39 ± 6.17 | 3.57 ± 5.99 | NS |
SF-MPQ affective [points] (mean ± SD) | 0.99 ± 1.89 | 1.50 ± 2.24 | 0.73 ± 1.63 | NS |
VAS [points] (mean ± SD) | 1.92 ± 2.65 | 2.32 ± 2.93 | 1.72 ± 2.48 | NS |
Characteristic (Mean ± SD) | Whole Population (n = 106) | Females (n = 36) | Males (n = 70) | p |
---|---|---|---|---|
HADS Total score [points] | 10.40 ± 7.47 | 13.11 ± 7.93 | 9.00 ± 6.86 | 0.005 |
HADS-A [points] | 6.25 ± 4.52 | 8.42 ± 4.85 | 5.14 ± 3.92 | <0.001 |
HADS-D [points] | 4.14 ± 3.68 | 4.69 ± 3.85 | 3.86 ± 3.58 | NS |
GAD-7 [points] | 6.01 ± 5.16 | 7.50 ± 5.58 | 5.24 ± 4.79 | 0.036 |
PHQ-9 [points] | 6.86 ± 5.98 | 8.61 ± 6.18 | 5.96 ± 5.71 | 0.021 |
DLQI [points] | 8.09 ± 6.99 | 9.83 ± 7.70 | 7.20 ± 6.47 | NS |
6-ISS [points] | 4.72 ± 3.63 | 5.39 ± 4.14 | 4.37 ± 3.32 | NS |
Characteristic (Mean ± SD) | Skin Pain in the Past Week (n = 53) | No Skin Pain in the Past Week (n = 53) | p |
---|---|---|---|
HADS Total score [points] | 12.17 ± 8.47 | 8.62 ± 5.868 | 0.043 |
HADS-A [points] | 7.42 ± 5.09 | 5.09 ± 3.54 | 0.022 |
HADS-D [points] | 4.75 ± 4.13 | 3.53 ± 3.08 | NS |
GAD-7 [points] | 6.62 ± 5.65 | 5.40 ± 4.59 | NS |
PHQ-9 [points] | 8.21 ± 6.72 | 5.51 ± 4.83 | 0.035 |
DLQI [points] | 10.58 ± 7.29 | 5.60 ± 5.73 | <0.001 |
6-ISS [points] | 5.23 ± 3.76 | 4.21 ± 3.50 | NS |
Characteristic (Mean ± SD) | Skin Pain in the Past Week (n = 53) | No Skin Pain in the Past Week (n = 53) | p |
---|---|---|---|
HADS abnormal score | 20 (37.7%) | 7 (13.2%) | 0.004 |
Anxiety | |||
HADS-A | 22 (41.5%) | 12 (22.6%) | 0.037 |
GAD-7 | 16 (30.2%) | 22 (41.5%) | NS |
Minimal anxiety | 24 (45.3%) | 24 (45.3%) | NS |
Mild anxiety | 15 (28.3%) | 22 (41.5%) | |
Moderate anxiety | 9 (17.0%) | 4 (7.5%) | |
Severe anxiety | 5 (9.4%) | 3 (5.7%) | |
Depression | |||
HADS-D | 11 (20.8%) | 5 (9.4%) | NS |
PHQ-9 | 18 (34.0%) | 12 (22.6%) | NS |
Minimal depression | 20 (37.7%) | 32 (60.4%) | 0.05 |
Mild depression | 16 (30.2%) | 14 (26.4%) | |
Moderate depression | 10 (18.9%) | 4 (7.5%) | |
Moderately severe depression | 3 (5.7%) | 3 (5.7%) | |
Severe depression | 4 (7.5%) | 0 (0%) | |
Quality of life | |||
Minimal impact | 3 (5.7%) | 17 (32.1%) | 0.002 |
Small impact | 15 (28.3%) | 15 (28.3%) | |
Moderate impact | 12 (22.6%) | 13 (24.5%) | |
Large impact | 16 (30.2%) | 6 (11.3%) | |
Extremely large impact | 7 (13.2%) | 2 (3.8%) |
Pain NRS in the Past Week | SF-MPQ Total Score | SF-MPQ Sensory | SF-MPQ Affective | VAS | |
---|---|---|---|---|---|
HADS Total score | NS | p = 0.021 | p = 0.038 | p = 0.039 | NS |
HADS-A | NS | p < 0.001 | p = 0.001 | p < 0.001 | NS |
HADS-D | NS | p = 0.038 | p = 0.037 | NS | NS |
GAD-7 | NS | NS | NS | NS | NS |
PHQ-9 | NS | p < 0.001 | p < 0.001 | p < 0.001 | p = 0.022 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kotewicz, M.; Krajewski, P.K.; Jaworek, A.K.; Szepietowski, J.C. Psychological Aspects of Cutaneous Pain in Psoriasis. J. Clin. Med. 2024, 13, 4890. https://doi.org/10.3390/jcm13164890
Kotewicz M, Krajewski PK, Jaworek AK, Szepietowski JC. Psychological Aspects of Cutaneous Pain in Psoriasis. Journal of Clinical Medicine. 2024; 13(16):4890. https://doi.org/10.3390/jcm13164890
Chicago/Turabian StyleKotewicz, Magdalena, Piotr K. Krajewski, Andrzej K. Jaworek, and Jacek C. Szepietowski. 2024. "Psychological Aspects of Cutaneous Pain in Psoriasis" Journal of Clinical Medicine 13, no. 16: 4890. https://doi.org/10.3390/jcm13164890